March 16, 2026
Good vibes or just vibes?
Scientists discover a surprising way to quiet the anxious mind (2025)
LSD pill to calm anxiety? Internet splits: hope, side‑eye, and memes
TLDR: A lab-made LSD dose (MM120) eased anxiety more than standard meds in a trial, with mild side effects under supervision. Comments split between hope, fatigue at “drugs are amazing” headlines, Bill Hicks memes, and fears that stigma will block access—making this a big, buzzy moment for mental health treatment debates
Scientists say a lab-made LSD pill, MM120, calmed anxious minds in a UCSF-led trial—and the comments lost it. Supporters like Rygian argued the real shock isn’t the “LSD” headline, but that a single dose beat standard meds many patients say barely help. One user mourned they’ll “never be able to try” it because of stigma, while skeptics like kykat rolled their eyes at yet another “drugs are amazing” front-page moment. The comedy crowd arrived too, dropping the classic Bill Hicks line about cosmic oneness and “Here’s Tom with the weather,” while another quipped that pairing “quiet mind” with LSD is “everything but quiet.”
Here’s the simple version: MM120 is a pharmaceutical, clinic-only form of LSD used under supervision at places like UCSF. In about 200 people with moderate-to-severe generalized anxiety (constant, exhausting worry), one guided dose cut symptoms by 5–6 points beyond placebo—often enough to nudge “moderate” toward “mild,” per a JAMA paper. Side effects were mostly mild (nausea, visual distortions, headaches), the highest dose didn’t work better, and patients were monitored. The community mood? A three-way split: hopeful this finally helps where everyday antidepressants don’t; tired of hype cycles; and worried that laws and stigma will keep real patients from ever seeing it. In short: science says “promising,” the internet says “prove it—and let us access it.”
Key Points
- •UCSF researchers are testing MM120, a pharmaceutical LSD formulation, as a treatment for generalized anxiety disorder.
- •In a JAMA-published earlier phase with ~200 moderate-to-severe GAD participants, a single MM120 dose reduced symptoms by 5–6 points beyond placebo over 12 weeks.
- •Standard SSRIs like Zoloft and Paxil reportedly average a 1.25-point improvement on a 56-point anxiety scale.
- •Side effects from MM120 were mostly mild to moderate (hallucinations, visual distortions, nausea, headache), more frequent at the highest, no-more-effective dose.
- •Nausea was mitigated with a light breakfast and preventive anti-nausea medication; researchers are recruiting individuals with disabling GAD symptoms.